On June 15, 2016, Renaissance Holdings completed the sale of its non-sterile, topicals-focused specialty and generics business, which includes Renaissance Pharma, to Mylan. A global pharmaceutical company committed to setting new standards in healthcare, Mylan’s mission is to provide the world’s 7 billion people access to high quality medicine. Learn more about Mylan.
Mylan Completes Acquisition of Renaissance’s Leading Topicals-Focused Specialty and Generics Business
June 15, 2016 – /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has successfully completed the acquisition of the non-sterile, topicals-focused specialty and generics business (the “Business”) of Renaissance Acquisition Holdings, LLC (“Renaissance”). Read more on Mylan.com.
Renaissance Pharma is in compliance with California’s Comprehensive Compliance Program and section AB128. A copy of the Compliance Program and written declaration can be obtained by calling 1-866-897-5002 toll free or by clicking here.